RecBio Raises $227 Million for Novel Genetically Engineered Vaccines
November 18, 2020 at 22:23 PM EST
RecBio, a Taizhou company that makes genetically engineered biotech vaccines for major diseases, completed a $227 million Series B round. Founded in 2012, the company is developing recombinant vaccines for human papillomavirus (HPV), zoster, tuberculosis and COVID. RecBio will use the proceeds to build a production base and to conduct clinic tests of its 9-valent HPV vaccine and recombinant COVID vaccine. The funding was led by Legend Capital and Lyfe Capital. More details.... Share this with colleagues: // //